
    
      This is a Phase IIa randomized, double-blind, placebo-controlled, single dose study to
      compare the safety, tolerability and PK/PDyn of intranasal L-dopa following administration of
      INP103 in the presence of L-dopa decarboxylase inhibitor (DCI) during an OFF episode.
    
  